To determine whether the serum FSTL1 level associated with liver pathology in humans, we analyzed specimens from 43 healthy participants, 43 patients with steatosis, 41 patients with early NASH and 53 with advanced NASH. This evidence concerns the gene FSTL1 and metabolic dysfunction-associated steatohepatitis.